News & Updates

COVID-19 patients with chronic statin exposure appear to be at lower risk of developing acute kidney injury (AKI) during hospitalization in addition to having reduced levels of inflammation, as reported in a study.

Treatment with the nucleos(t)ide analogue (NUC) tenofovir alafenamide (TAF) for 2 years leads to improvements in liver stiffness among patients with chronic hepatitis B (CHB), including those with advanced liver fibrosis, according to a study presented at the IDWeek 2022 in Washington, DC, US.

Drinking 2–3 cups of coffee – be it ground, instant, or decaffeinated – daily is consistently associated with significant reductions in the risks of cardiovascular disease (CVD), coronary heart disease (CHD), congestive cardiac failure (CCF), and all-cause mortality in a new analysis of the UK Biobank study.

Olfactory and gustatory** loss/alterations are common COVID-19 symptoms, but recovery is expected in most patients within the first 3 months. However, these dysfunctions may persist in some individuals, according to a reconstructed meta-analysis from Singapore.

Cefepime-taniborbactam (FTB) is significantly better than meropenem for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), according to results of the Cefepime Rescue with Taniborbactam in cUTI (CERTAIN-1) study presented at the recent ID Week 2022.

The use of metformin does not appear to confer any benefits in terms of reducing the risk of older-onset inflammatory bowel disease (IBD), a study has found.

Among women suffering from endometriosis, treatment with silymarin leads to lowered interleukin (IL)-6 concentrations, smaller endometrioma lesions, and eased pain, a recent study has found.